Clinical scenario {#sa1-s1}
=================

A 55-year-old man presents to your ED with shortness of breath and fever for a few days. A nasopharyngeal swab confirms a COVID-19 infection. As an evidence-based doctor, you have been pretty active at following emerging potential treatments and wonder if treatment with remdesivir would improve your patient's clinical course.

Three-part question {#sa1-s2}
===================

In \[adult patients with confirmed COVID-19 infection\] does treatment with \[remdesivir\] improve \[clinical outcome\]?

Search strategy {#sa1-s3}
===============

OVID MEDLINE 1946 to June 19 2020

\[Coronavirus.exp OR coronavirus.mp OR COVID-19.mp OR sars-cov-2.mp OR SARS\$.mp OR coroa\$.mp\] AND \[remdesivir.mp OR GS-5734.mp\]

Search limited to English language and humans

75 Papers found of which three were deemed relevant

Embase 1996 to 2020 week 25

\[Coronavirus.mp OR coronavirinae.exp OR COVID-19.mp OR SARS coronavirus.exp OR sars-cov-2.mp OR corona\$.mp OR SARS\$.mp\] AND \[remdesivir.mp OR remdesivir.exp OR GS-5734.mp\]

Search limited to English Language and humans

422 papers found of which five were deemed relevant

[Table 1](#T1){ref-type="table"} below summarises the relevant included studies after duplicates were excluded.

###### 

Relevant papers

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, date, country                     Patient group                                                                                                                                                               Study type                                                      Outcomes measured                                                      Results found                                                                                            Study weaknesses
  ----------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------
  S Antinori *et al*, Italy[@SA1-R1] 2020   35 patients over 18 years of age with confirmed COVID-19 infection requiring mechanical ventilation or had SpO~2~ ≤94% on room air or national early warning score of ≥4\   Open-label prospective study                                    Hospitalisation status as primary outcome\                             At day 28, 82.3% of patients on the infectious disease ward were discharged and 5.9% had died\           Presence of confounding factors\
                                            18 patients were recruited in the intensive care unit and 17 in the infectious disease ward\                                                                                                                                                Side effects as secondary outcomes                                     33.3% were discharged from intensive care and 44.4% had died with 16.7% still mechanically ventilated\   No control group\
                                            Patients were allowed to continue their other treatments (including hydroxychloroquine) but had to discontinue other antivirals\                                                                                                                                                                                   Hepatotoxicity in 42.8% as most common side effect                                                       Open-label compassionate single-centre trial\
                                            37% discontinued the intervention because of side effects                                                                                                                                                                                                                                                                                                                                                                   Small size cohort

  J Grein *et al*., 2020[@SA1-R2]           53 patients with confirmed COVID-19 infection with SpO~2~ ≤94% or who received oxygen support received at least one dose of remdesivir as intervention                      Multicentre prospective study                                   Improvement in oxygen support, hospital discharge and adverse events   At day 28, the cumulative incidence of improvement was 84%\                                              No clearly pre-defined endpoints\
                                                                                                                                                                                                                                                                                                                                                               (95% CI 70 to 99)\                                                                                       Open-label compassionate trial\
                                                                                                                                                                                                                                                                                                                                                               Overall mortality was 0.56 per 100 hospitalisations\                                                     Small size cohort\
                                                                                                                                                                                                                                                                                                                                                               (95% CI 0.14 to 0.97)\                                                                                   No control group\
                                                                                                                                                                                                                                                                                                                                                               23% of patients developed severe adverse events                                                          Short duration of follow-up

  J Goldman *et al*., USA 2020[@SA1-R3]     Patients with COVID-19 infection with SpO~2~≤94% or receiving supplemental oxygen therapy and radiological evidence of pneumonia\                                           Randomised, open-label multicentre trial                        Clinical status at day 14 based on an ordinal scale\                   After adjustment for clinical status, both patient groups had similar outcome at day 14 (p=0.14)\        No placebo control group\
                                            200 patients received remdesivir for 5 days and 197 for 10 days\                                                                                                                                                                            Adverse events as secondary outcomes                                   70% of patients in the 5-day group experienced adverse events vs 74% in the 10-day group                 Results cannot be extrapolated to critically ill patients
                                            Patients requiring ventilatory support at baseline were excluded                                                                                                                                                                                                                                                                                                                                                            

  J Beigel *et al*., 2020[@SA1-R4]          1063 patients with COVID-19 infection and confirmed lower respiratory tract involvement\                                                                                    Multicentre double-blind, randomised placebo-controlled trial   Time to recovery\                                                      The intervention group had a shorter recovery time (median days 11 vs 15 in the placebo group)\          Potential confounders\
                                            541 randomised to remdesivir and 522 to placebo\                                                                                                                                                                                            Serious adverse events                                                 Rate ratio 1.32 (95% CI 1.12 to 1.55, p\<0.001)\                                                         Unclear what was defined as lower respiratory involvement\
                                            Patients were allowed to receive other supportive treatments                                                                                                                                                                                                                                                       Mortality in the intervention group was 7.1% vs 11.9%\                                                   Full statistical analysis still ongoing (preliminary report)
                                                                                                                                                                                                                                                                                                                                                               HR 0.70 (95% CI 0.47 to 1.04)\                                                                           
                                                                                                                                                                                                                                                                                                                                                               Serious adverse events occurred in 21.1% in the intervention group vs 27% in the placebo one             

  Wang *et al*., China 2020[@SA1-R5]        237 patients with COVID-19 pneumonia confirmed with imaging with SpO~2~ ≤94% or PaO~2~/FiO~2~ ≤300 mm Hg\                                                                   Multicentre double-blind, randomised placebo-controlled trial   Clinical improvement\                                                  Intervention was not found to be liked to improvement (median 21 days vs 23 in placebo)\                 Potential confounders\
                                            158 assigned to intervention and 79 to placebo (2:1 randomisation)\                                                                                                                                                                         Adverse events                                                         HR 1.23 (95% CI 0.87 to 1.75)\                                                                           Intervention seems to have been started relatively late\
                                            Patients allowed concomitant use of ani-retrovirals, corticosteroids and interferons                                                                                                                                                                                                                               28-day mortality 14% vs 13%, difference 1.1% (95% CI −8.1 to 10.3)\                                      Underpowered as the study was terminated early
                                                                                                                                                                                                                                                                                                                                                               66% patients in the intervention group displayed adverse events vs 64% in the control group              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion {#sa1-s4}
==========

Although several approved drugs have shown some antiviral activity against SARS-CoV-2 in in vitro settings, there are no antiviral therapies of proven benefit in treating patients infected with this emerging infection. Remdesivir is an adenosine prodrug that inhibits all human and animal coronaviruses in vitro so it was felt it would show some promising results in human trials.

This is a rapidly evolving picture with ongoing clinical trials at time of publication.

Several smaller trials[@SA1-R1] have been published to date, but two larger trials however merit further attention and scrutiny.

Wang *et al* [@SA1-R4] were unable to demonstrate any statistically significant clinical benefits for remdesivir but failed to complete full recruitment as set out at start of the trial due to the end of the outbreak. At the time of review and publication, we only had access to the preliminary report for the trial by Beigel *et al*,[@SA1-R5] the largest trial to date. The authors' conclusions were that remdesivir was of benefit for in-patients requiring supplemental oxygen but also cautioned that in view of the high mortality rate despite its use, remdesivir was unlikely to be sufficient alone.

###### Clinical bottom line

Further larger-scale and well-designed clinical trials are needed to establish the exact role of remdesivir in the treatment of COVID-19 infections.
